# EDGAR Filing Document

**Accession Number:** 0001921865
**File Stem:** 0001477932-26-003379
**Filing Date:** 2026-5
**Character Count:** 27923
**Document Hash:** 085ef30df1862bbf9cb5c82cc0ff36e6
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001477932-26-003379.hdr.sgml**: 20260622

**ACCESSION NUMBER**: 0001477932-26-003379

**CONFORMED SUBMISSION TYPE**: S-8

**PUBLIC DOCUMENT COUNT**: 15

**FILED AS OF DATE**: 20260521

**DATE AS OF CHANGE**: 20260520

**EFFECTIVENESS DATE**: 20260521

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** ASP Isotopes Inc.
- **CENTRAL INDEX KEY:** 0001921865
- **STANDARD INDUSTRIAL CLASSIFICATION:** MISCELLANEOUS CHEMICAL PRODUCTS [2890]
- **ORGANIZATION NAME:** 08 Industrial Applications and Services
- **EIN:** 872618235
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** S-8
- **SEC ACT:** 1933 Act
- **SEC FILE NUMBER:** 333-296095
- **FILM NUMBER:** 261005491

**BUSINESS ADDRESS:**
- **STREET 1:** 2200 ROSS AVENUE, SUITE 4575E
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75201
- **BUSINESS PHONE:** 202-756-2245

**MAIL ADDRESS:**
- **STREET 1:** 2200 ROSS AVENUE, SUITE 4575E
- **CITY:** DALLAS
- **STATE:** TX
- **ZIP:** 75201

**As filed with the Securities and Exchange Commission on May 20, 2026**

**Registration No. 333-** 

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**WASHINGTON, D.C. 20549**

___________________

**FORM S**-**8**

**REGISTRATION STATEMENT**

**UNDER**

**THE SECURITIES ACT OF 1933**

___________________

---

| |
|:---|
| **ASP ISOTOPES INC.** |
| (Exact name of registrant as specified in its charter) |

---

---

| | |
|:---|:---|
| **Delaware** | **87-2618235** |
| (State or other jurisdiction of<br> incorporation or organization) | (I.R.S. Employer<br> Identification No.) |

---

**2200 Ross Avenue, Suite 4575E**

**<u>Dallas, TX 75201</u>**

(Address of Principal Executive Offices) (Zip Code)

_________________

**<u>ASP ISOTOPES INC. 2025 INDUCEMENT EQUITY INCENTIVE PLAN</u>**

(Full title of the plan)

___________________

**Paul E. Mann**

**Executive Chairman and Chief Executive Officer**

**ASP Isotopes Inc.**

**2200 Ross Avenue, Suite 4575E**

**<u>Dallas, TX 75201</u>**

(Name and address of agent for service)

**<u>(214) 432-8219</u>**

(Telephone number, including area code, of agent for service)

***Copy to:***

**Yelena Barychev**

**Blank Rome LLP**

**One Logan Square**

**Philadelphia, PA 19103**

**Tel: (215) 569-5737**

 **Fax: (832) 569-5727**

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer a smaller reporting company or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer ☐ Accelerated filer ☐ <br> Non-accelerated filer ☒ Smaller reporting company ☒ <br> Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 7(a)(2)(B) of the Securities Act ☐

**Explanatory Note**

ASP Isotopes Inc. (the "Registrant", the "Company", "we" or "us") is filing this Registration Statement on Form S-8 under the Securities Act of 1933, as amended (the "Securities Act"), to register 2,000,000 shares of its common stock, par value $0.01 per share, reserved for issuance to eligible persons under the Company's 2025 Inducement Equity Incentive Plan (the "Inducement Equity Plan"). The Inducement Equity Plan is used exclusively for the grant of equity awards to individuals who were not previously employees or directors of the Company, or following a bona fide period of non-employment, as an inducement material to such individuals entering into employment with the Company, pursuant to Nasdaq Listing Rule 5635(c)(4).

**PART I**

**INFORMATION REQUIRED IN THE SECTION 10(A) PROSPECTUS**

The information specified in Item 1 and Item 2 of Part I of this Registration Statement is omitted from this filing in accordance with the provisions of Rule 428 under the Securities Act and the introductory note to Part I of Form S-8. The documents containing the information specified in Part I will be delivered to plan participants as required by Rule 428(b)(1). These documents and the documents incorporated by reference into this Registration Statement pursuant to Item 3 of Part II of this Registration Statement, taken together, constitute a prospectus that meets the requirements of Section 10(a) of the Securities Act.

**PART II**

**INFORMATION REQUIRED IN THE REGISTRATION STATEMENT**

**Item 3. Incorporation of Documents by Reference.**

The following documents previously filed by the Registrant with the Securities and Exchange Commission (the "Commission") are incorporated by reference into this Registration Statement:

(a) the Registrant's Annual Report on Form 10-K for the year ended December 31, 2025, filed with the Commission on April 10, 2026, as amended by Amendment No. 1 to the Registrant's Annual Report on Form 10-K/A, filed with the Commission on April 30, 2026;

(b) the Registrant's Current Reports on Form 8-K filed with the Commission on May 27, 2025; January 7, 2026, as amended by Amendment No. 1 to the Current Report on Form 8-K/A filed with the Commission on March 24, 2026; January 12, 2026; and January 30, 2026;

(c) the Registrant's Quarterly Report on Form 10-Q for the quarter ended March 31, 2026, filed with the Commission on May 20, 2026; and

(d) the description of the Registrant's common stock contained in Exhibit 4.1 incorporated by reference into the Registrant's Annual Report on Form 10-K filed with the Commission on April 10, 2026, including any amendments or reports filed for the purpose of updating such description.

All documents subsequently filed by the Registrant with the Commission pursuant to Sections 13(a), 13(c), 14, or 15(d) of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), prior to the filing of a post-effective amendment to the Registration Statement which indicates that all securities offered have been sold or which deregisters all securities then remaining unsold, shall be deemed incorporated by reference into this Registration Statement and to be a part hereof from the date of the filing of such documents.

The Registrant is not incorporating by reference any information or document, or portion thereof, whether specifically listed above or to be filed in the future, that is furnished to, and is not deemed "filed" with, the Commission. Any statement contained in a document incorporated or deemed to be incorporated by reference in this Registration Statement shall be deemed to be modified or superseded for purposes of this Registration Statement to the extent that a statement contained in this Registration Statement, or in any other subsequently filed document which also is, or is deemed, to be incorporated by reference in this Registration Statement, modifies or supersedes such earlier statement. Any statement so modified or superseded shall not be deemed, except as so modified or superseded, to constitute a part of this Registration Statement.

**Item 4. Description of Securities.**

Not applicable.

**Item 5. Interests of Named Experts and Counsel.**

Not applicable.

**Item 6. Indemnification of Directors and Officers.**

The following summary is qualified in its entirety by reference to the provisions of the Delaware General Corporation Law ("DGCL") and the registrant's Amended and Restated Certificate of Incorporation (the "Certificate of Incorporation"), and Amended and Restated Bylaws (the "Bylaws").

Section 145 of the DGCL provides, generally, that a corporation shall have the power to indemnify any person who was or is a party or is threatened to be made a party to any threatened, pending or completed action, suit or proceeding (except actions by or in the right of the corporation) by reason of the fact that such person is or was a director, officer, employee or agent of the corporation against all expenses, judgments, fines and amounts paid in settlement actually and reasonably incurred by such person in connection with such action, suit or proceeding if such person acted in good faith and in a manner such person reasonably believed to be in or not opposed to the best interests of the corporation and, with respect to any criminal action or proceeding, had no reasonable cause to believe his or her conduct was unlawful. A corporation may similarly indemnify such person for expenses actually and reasonably incurred by such person in connection with the defense or settlement of any action or suit by or in the right of the corporation, provided that such person acted in good faith and in a manner he or she reasonably believed to be in or not opposed to the best interests of the corporation, and, in the case of claims, issues and matters as to which such person shall have been adjudged liable to the corporation, provided that a court shall have determined, upon application, that, despite the adjudication of liability but in view of all of the circumstances of the case, such person is fairly and reasonably entitled to indemnity for such expenses which such court shall deem proper.

The registrant's Certificate of Incorporation and Bylaws provide for indemnification of the registrant's directors and officers to the fullest extent permitted by law. Insofar as indemnification for liabilities under the Securities Act of 1933, as amended (the "Securities Act") may be permitted for directors, officers or controlling persons of the registrant pursuant to the registrant's Certificate of Incorporation, Bylaws and the DGCL, the registrant has been informed that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable.

Section 102(b)(7) of the DGCL provides that a certificate of incorporation may include a provision that eliminates or limits the personal liability of a director to the corporation or its stockholders for monetary damages for breach of fiduciary duty as a director, except for liability (i) for any breach of the director's duty of loyalty to the Company or its stockholders, (ii) for acts or omissions not in good faith or that involve intentional misconduct or a knowing violation of law, (iii) under Section 174 of the DGCL, relating to prohibited dividends or distributions or the repurchase or redemption of stock or (iv) for any transaction from which the director derives an improper personal benefit. The registrant's Certificate of Incorporation includes such a provision. As a result of this provision, the registrant and its stockholders may be unable to obtain monetary damages from a director for breach of his or her duty of care.

As permitted under the DGCL, the registrant has entered into indemnification agreements with its directors and officers, whereby it has agreed to indemnify its directors and officers to the fullest extent permitted by law, including indemnification against expenses and liabilities incurred in legal proceedings to which the director or officer was, or is threatened to be made, a party by reason of the fact that such director or officer is or was a director, officer, employee or agent of the registrant, provided that such director or officer acted in good faith and in a manner that the director or officer reasonably believed to be in, or not opposed to, the best interest of the registrant. The indemnification agreements also set forth certain procedures, presumptions and remedies that will apply in the event of a claim for indemnification thereunder.

The Inducement Equity Plan provides, subject to certain limitations, for indemnification by us of any director, officer, or employee against all reasonable expenses, including attorneys' fees, incurred in connection with any legal action arising from such person's action or failure to act in administering the Inducement Equity Plan.

We maintain insurance policies that indemnify our directors and officers against various liabilities arising under the Securities Act and the Exchange Act that might be incurred by any director or officer in his or her capacity as such.

**Item 7. Exemption from Registration Claimed.**

Not applicable.

**Item 8. Exhibits.**

**(a) Exhibits**

---

| | | |
|:---|:---|:---|
| **Exhibit** <br> **Number** | **Exhibit** <br> **Title** | **Filed** <br> **Herewith** |
| [5.1](aspi_ex51.htm) | [Opinion of Blank Rome LLP](aspi_ex51.htm) | X |
| [23.1](aspi_ex231.htm) | [Consent of Independent Registered Public Accounting Firm](aspi_ex231.htm) | X |
| [23.2](aspi_ex232.htm) | [Consent of BDO South Africa Incorporated](aspi_ex232.htm) | X |
| [23.3](aspi_ex51.htm) | [Consent of Blank Rome LLP (included in Exhibit 5.1)](aspi_ex51.htm) | X |
| [24.1](#poa) | [Power of Attorney (included on the signature page)](#poa) | X |
| [99.1](http://www.sec.gov/Archives/edgar/data/1921865/000095017025108971/aspi-ex10_1.htm) | [ASP Isotopes Inc. 2025 Inducement Equity Incentive Plan (incorporated by reference into Exhibit 10.1 to the Quarterly Report on Form 10-Q filed with the Commission on August 14, 2025)](http://www.sec.gov/Archives/edgar/data/1921865/000095017025108971/aspi-ex10_1.htm) |  |
| [107](aspi_ex107.htm) | [Filing Fee Table](aspi_ex107.htm) | X |

---

**Item 9. Undertakings.**

(a) The undersigned Registrant hereby undertakes:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(1) To file, during any period in which offers or sales are being made, a post-effective amendment to this Registration Statement:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(i) To include any prospectus required by Section 10(a)(3) of the Securities Act;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(ii) To reflect in the prospectus any facts or events arising after the effective date of the Registration Statement (or the most recent post-effective amendment thereof) which, individually or in the aggregate, represent a fundamental change in the information set forth in the Registration Statement; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(iii) To include any material information with respect to the plan of distribution not previously disclosed in the Registration Statement or any material change to such information in the Registration Statement; *provided, however*, that paragraphs (a)(1)(i) and (a)(1)(ii) do not apply if the information required to be included in a post-effective amendment by those paragraphs is contained in reports filed with or furnished to the Commission by the Registrant pursuant to Section 13 or Section 15(d) of the Exchange Act that are incorporated by reference in the Registration Statement.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(2) That, for the purpose of determining any liability under the Securities Act, each such post-effective amendment shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;(3) To remove from registration by means of a post-effective amendment any of the securities being registered which remain unsold at the termination of the offering.

(b) The undersigned Registrant hereby undertakes that, for purposes of determining any liability under the Securities Act, each filing of the Registrant's annual report pursuant to Section 13(a) or Section 15(d) of the Exchange Act (and, where applicable, each filing of an employee benefit plan's annual report pursuant to Section 15(d) of the Exchange Act) that is incorporated by reference in the Registration Statement shall be deemed to be a new registration statement relating to the securities offered therein, and the offering of such securities at that time shall be deemed to be the initial *bona fide* offering thereof.

(c) Insofar as indemnification for liabilities arising under the Securities Act may be permitted to directors, officers and controlling persons of the Registrant pursuant to the foregoing provisions, or otherwise, the Registrant has been advised that in the opinion of the Commission such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. In the event that a claim for indemnification against such liabilities (other than the payment by the Registrant of expenses incurred or paid by a director, officer or controlling person of the Registrant in the successful defense of any action, suit or proceeding) is asserted by such director, officer or controlling person in connection with the securities being registered, the Registrant will, unless in the opinion of its counsel the matter has been settled by controlling precedent, submit to a court of appropriate jurisdiction the question whether such indemnification by it is against public policy as expressed in the Securities Act and will be governed by the final adjudication of such issue.

**SIGNATURES**

Pursuant to the requirements of the Securities Act of 1933, as amended, the Registrant certifies that it has reasonable grounds to believe that it meets all of the requirements for filing on Form S-8 and has duly caused this Registration Statement to be signed on its behalf by the undersigned, thereunto duly authorized, in the City of Dallas, Texas, on May 20, 2026.

---

| | |
|:---|:---|
| **ASP ISOTOPES INC.** | **ASP ISOTOPES INC.** |
| By | */s/ Paul E. Mann* |
|  | Paul E. Mann<br> Executive Chairman and Chief Executive Officer |

---

**POWER OF ATTORNEY**

KNOW ALL PERSONS BY THESE PRESENTS, that that each person whose signature appears below constitutes and appoints Paul E. Mann and Heather Kiessling, and each of them, as such person's true and lawful attorney-in-fact and agent, with full power of substitution and resubstitution, for such person and in such person's name, place and stead, in any and all capacities, to sign any and all amendments, including post-effective amendments, to this Registration Statement, and to file the same, with all exhibits thereto and other documents in connection therewith, with the Commission, granting unto said attorneys-in-fact and agents, and each of them, full power and authority to do and perform each and every act and thing requisite and necessary to be done, as fully for all intents and purposes as such person might or could do in person, hereby approving, ratifying and confirming all that each of said attorneys-in-fact and agents or their substitute or substitutes may lawfully do or cause to be done by virtue thereof.

Pursuant to the requirements of the Securities Act of 1933, as amended, this Registration Statement has been signed below by the following persons in the capacities and on the dates indicated.

---

| | | |
|:---|:---|:---|
| **Signature** | **Title** | **Date** |
| */s/ Paul E. Mann* | Executive Chairman, Director and Chief Executive Officer (*Principal Executive Officer*) | May 20, 2026 |
| Paul E. Mann | Executive Chairman, Director and Chief Executive Officer (*Principal Executive Officer*) | May 20, 2026 |
| */s/ Heather Kiessling* | Chief Financial Officer<br> (*Principal Financial and Accounting Officer*) | May 20, 2026 |
| Heather Kiessling | Chief Financial Officer<br> (*Principal Financial and Accounting Officer*) | May 20, 2026 |
|  | Director | May 20, 2026 |
| Michael Gorley, Ph.D. | Director | May 20, 2026 |
| */s/ Ralph L. Hunter, Jr.* | Director | May 20, 2026 |
| Ralph L. Hunter, Jr. | Director | May 20, 2026 |
| */s/ Sipho N. Maseko* | Director | May 20, 2026 |
| Sipho N. Maseko | Director | May 20, 2026 |
| */s/ Duncan Moore, Ph.D.* | Director | May 20, 2026 |
| Duncan Moore, Ph.D. | Director | May 20, 2026 |
|  | Director | May 20, 2026 |
| Robert Ryan | Director | May 20, 2026 |
| */s/ Todd Wider, M.D.* | Director | May 20, 2026 |
| Todd Wider, M.D. | Director | May 20, 2026 |

---

## Exhibit 5.1

**EXHIBIT 5.1**

![](aspi_ex51img1.jpg)

One Logan Square

130 North 18th Street \|Philadelphia, PA 19103-6998

www.blankrome.com

May 20, 2026

The Board of Directors

ASP Isotopes Inc.

2200 Ross Avenue, Suite 4575E

Dallas, TX 75201

---

| | |
|:---|:---|
| **Re:** | **ASP Isotopes Inc.**<br> **<u>Registration Statement on Form S-8</u>** |

---

Ladies and Gentlemen:

We have acted as counsel to ASP Isotopes Inc., a Delaware corporation (the "<u>Company</u>"), in connection with the preparation of a Registration Statement on Form S-8 (the "<u>Registration Statement</u>") to be filed by the Company with the Securities and Exchange Commission (the "<u>Commission</u>") under the Securities Act of 1933, as amended (the "<u>Securities Act</u>"), relating to the offer and sale of up to 2,000,000 shares (the "<u>Shares</u>") of common stock of the Company, par value $0.01 per share ("<u>Common Stock</u>"), issuable under the Company's 2025 Inducement Equity Incentive Plan (the "<u>Plan</u>"). This opinion is furnished pursuant to the requirements of Item 601(b)(5) of Regulation S-K.

Although as counsel to the Company we have advised the Company in connection with a variety of matters referred to us by it, our services are limited to specific matters so referred. Consequently, we do not have knowledge of many transactions in which the Company has engaged or its day-to-day operations.

In rendering this opinion, we have examined the following documents: (i) the Amended and Restated Certificate of Incorporation of the Company; (ii) the Amended and Restated Bylaws of the Company; (iii) resolutions adopted by the Compensation Committee of the Board of Directors (the "<u>Board</u>") of the Company; (iv) resolutions adopted by the Board of the Company; (v) a certificate from an officer of the Company; (vi) the Registration Statement (including all exhibits thereto); (vii) the Plan; and (viii) such other documents as we deem relevant and necessary as a basis for the opinion hereinafter expressed. We have not performed any independent investigation in rendering this opinion other than the document examination described. We have assumed and relied, as to questions of fact and mixed questions of law and fact, on the truth, completeness, authenticity and due authorization of all certificates, documents, and records examined and the genuineness of all signatures.

In rendering this opinion, we have assumed that, the Shares will be issued in accordance with the terms and conditions of the Plan, and that at the time of issuance of any Shares, there shall be a sufficient number of duly authorized and unissued shares of the Company's Common Stock to accommodate the issuance of the Shares.

Our opinion is limited to the General Corporation Law of the State of Delaware, as amended.

Based upon and subject to the foregoing and the qualifications and limitations set forth below, we are of the opinion that the Shares, when issued in accordance with the terms of the Plan, will be validly issued, fully paid and nonassessable.

This opinion is given as of the date hereof. We assume no obligation to update or supplement this opinion to reflect any facts or circumstances which may hereafter come to our attention or any changes in laws which may hereafter occur.

This opinion is strictly limited to the matters stated herein and no other or more extensive opinion is intended, implied or to be inferred beyond the matters expressly stated herein.

We consent to the filing of this opinion as an exhibit to the Registration Statement. In giving such consent, we do not thereby admit that we are included in the category of persons whose consent is required by the Securities Act or the rules and regulations promulgated by the Commission.

---

| |
|:---|
| Very truly yours, |
| /s/ Blank Rome LLP |
| Blank Rome LLP |

---

## Exhibit 23.1

**EXHIBIT 23.1**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement of ASP Isotopes Inc. on Form S-8 to be filed on or about May 20, 2026 of our report dated April 9, 2026, on our audits of the financial statements as of December 31, 2025 and 2024 and for each of the years then ended, which report was included in the Annual Report on Form 10-K filed April 10, 2026.

---

| |
|:---|
| */s/ EisnerAmper LLP* |
| EISNERAMPER LLP<br> Iselin, New Jersey<br> May 20, 2026 |

---

## Exhibit 23.2

**EXHIBIT 23.2**

**CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM**

We consent to the incorporation by reference in this Registration Statement of ASP Isotopes Inc. on Form S-8 of our report dated May 27, 2025, relating to the consolidated financial statements of Renergen Limited (the "Company"), which appear in the Form 8-K filed by ASP Isotopes Inc. on May 27, 2025. Our report contains a material uncertainty explanatory paragraph regarding the Company's ability to continue as a going concern.

---

| |
|:---|
| /s/ BDO South Africa Inc. |
| **BDO SOUTH AFRICA INCORPORATED** |
| Johannesburg, South Africa |
| Wanderers Office Park<br> 52 Corlett Drive<br> Illovo, 2196 |
| May 20, 2026 |

---

## Ex-Filing

?xml version='1.0' encoding='ASCII'? aspi_ex107.htm

**EXHIBIT 107**

**Calculation of Filing Fee Tables**

**FORM S-8**

REGISTRATION STATEMENT UNDER

THE SECURITIES ACT OF 1933

**ASP ISOTOPES INC.**

(Exact Name of Registrant as Specified in its Charter)

**Table 1: Newly Registered Securities**

---

| | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|
|  | **Security Type** | **Security Class Title** | **Fee Calculation Rule** | **Amount**<br>**Registered**<sup>(1)</sup> | **Proposed Maximum Offering Price Per Unit** | **Maximum Aggregate Offering Price** | **Fee Rate** | **Amount of Registration Fee** |
| Fees to be paid | Equity | Common stock, $0.01 par value per share | 457(c) and 457(h)(2) | 2000000<br><sup>(3)</sup> | $5.51<br><sup>(2)</sup> | $11020000 | $0.00013810 | $1521.86 |
|  | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** | **Total Offering Amounts** |  | $11020000 |  | $1521.86 |
|  | **Total Fee Offsets**<sup>(4)</sup> | **Total Fee Offsets**<sup>(4)</sup> | **Total Fee Offsets**<sup>(4)</sup> | **Total Fee Offsets**<sup>(4)</sup> |  |  |  | N/A  |
|  | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** | **Net Fee Due** |  |  |  | $1521.86 |

---

(1) Pursuant to Rule 416(a) of the Securities Act of 1933, as amended (the "Securities Act"), this Registration Statement shall also cover any additional shares of common stock, $0.01 par value per share ("Common Stock"), of ASP Isotopes Inc. (the "Registrant") that become issuable under the ASP Isotopes Inc. 2025 Inducement Equity Incentive Plan (the "2025 Plan") by reason of any stock dividend, stock split, recapitalization or other similar transaction effected without the receipt of consideration which results in an increase in the number of the outstanding shares of Common Stock.

(2) Estimated in accordance with Rules 457(c) and 457(h) under the Securities Act solely for the purpose of calculating the registration fee on the basis of $5.51 per share, which is the average of the high and low prices of the Registrant's Common Stock on May 18, 2026, as reported on the Nasdaq Capital Market.

(3) Represents 2,000,000 shares of Common Stock reserved for issuance under the 2025 Plan.

(4) The Registrant does not have any fee offsets.